Biovie is trading 5.8% up in after-hours at $1.83, with biotech-sector strength offering context, though sources do not establish it as the direct cause. - Shares gained 26.28% in the regular session on November 3, while the XBI rose 2.54%. - On November 2, BioVie announced it will present previously undisclosed Long COVID biomarker data on November 13; no separate November 3 after-hours announcement was identified.